IDEXX Laboratories will add mast cell tumor detection to its Cancer Dx Panel in North America starting mid-2026 at no additional cost to veterinary practices. The existing panel, used by more than 5,500 clinics across the U.S. and Canada, previously detected canine lymphoma up to eight months before clinical signs. With the new assay, the panel will cover over one-third of all canine cancer cases and deliver results within 2–3 days in the U.S. (2–4 days in Canada) using the same specimen and workflow. This enhancement enables veterinarians to screen at-risk dogs—defined as those aged seven years or older, or high-risk breeds aged four years or older—during routine wellness visits and to test symptomatic patients when mast cell tumors are suspected.

In late Q4 2025 IDEXX began a controlled rollout of Fine-Needle Aspiration (FNA) cytology on its inVue Dx Cellular Analyzer, with broad availability expected throughout 2026. The slide-free system allows same-visit analysis of skin masses, identifying and quantifying mast cell tumor cells without traditional slide preparation. Practices can order an expert review from an IDEXX pathologist directly through the platform. This in-clinic capability addresses one of veterinary oncology’s key challenges—rapid, accurate mass classification—and lays the foundation for future menu expansion to additional tumor types.

IDEXX has introduced the ImageVue DR50 Plus Digital Imaging System, delivering up to 25% lower radiation exposure compared to its prior DR50 model and up to 60% lower dose versus competing veterinary solutions. The system’s 14” x 17” and optional 17” x 17” panels use advanced signal capture and AI-driven image optimization to reduce retakes and improve diagnostic confidence. Integrated with IDEXX Web PACS software and 24/7 telemedicine consulting—featuring over 160 board-certified specialists—the system streamlines workflows, cutting case submission clicks by more than 45%.

These product launches reinforce IDEXX’s leadership in pet healthcare diagnostics and imaging, aligning with its mission to support longer, fuller lives for pets. The company employs approximately 11,000 people and serves customers in over 175 countries and territories. By expanding its reference laboratory services and in-clinic solutions, IDEXX aims to drive recurring revenue from diagnostic testing and capitalize on growing demand for proactive cancer screening and low-dose imaging in veterinary medicine.